Vascular Interventional Advances (VIVA)

The VIVA Foundation is a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education, research, advocacy, and collaboration. It hosts the VIVA (Vascular InterVentional Advances) and The VEINS (Venous Endovascular INterventional Strategies) annual conferences. The VIVA Foundation also presents the Vascular Leaders Forum and collaborates with other industry-leading groups to move the field forward.

Drug-coated balloons an effective tool in the battle against femoropopliteal disease
Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes.
Late-breaking study examines IVL’s safety and effectiveness among real-life PAD patients
The new study, based on data from nearly 1,400 PAD patients who were treated with Shockwave Medical's IVL technology, was presented at VIVA22 in Las Vegas.
Out on a Limb: Tackling the PAD Knowledge Gap to Save Legs & Lives
Peripheral artery disease is under scrutiny as the number of endovascular interventions has soared. In a field where clinical evidence is sparse, experts are asking how the financial and societal costs of revascularization compare with amputating the problem and whether early detection and treatment could save lives, limbs and perhaps healthcare dollars.
Data Drought: The Struggle to Build Evidence in Vascular Medicine & Intervention
How VIVA Physicians is working to answer questions about treatment of vascular disease.
VIVA.14: Promising 1-year results for drug-coated balloons in diabetics
Patients with peripheral artery disease (PAD) and diabetes who underwent treatment with a drug-coated balloon fared better than counterparts who received standard care, according to a subanalysis of the IN.PACT SFA trial.

Shockwave Medical’s lithoplasty system achieves primary endpoint in single-arm study

A single-arm study found that all of the patients with moderate or severely calcified peripheral lesions who received the lithoplasty system achieved the primary efficacy endpoint of procedural success.

September 29, 2016

Medtronic Valiant Captivia Demonstrates Safety and Efficacy at Three Years

Medtronic announced new data, demonstrating safety and efficacy at three years in acute complicated Type B aortic dissection patients treated with the Valiant Captivia Thoracic Stent Graft System. Ali Azizzadeh, MD, FACS, University of Texas Health Science Center in Texas presented the new clinical data in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2016.

September 21, 2016

Shockwave Medical Announces FDA Clearance of the Company’s Lithoplasty® System, the First and Only Technology to Use Sound Waves to Treat Calcified Peripheral Artery Disease

Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced clearance from the U.S. Food and Drug Administration (FDA) of the Lithoplasty System for the treatment of calcified plaque in patients with peripheral artery disease (PAD).

September 16, 2016

Viva Physicians announces late-breaking clinical trial lineup

Viva Physicians, a non-profit organization devoted to vascular interventions and medicine, announced the late-breaking clinical trials for its annual conference. The meeting will take place from September 18 to 22 in Las Vegas at the Wynn resort and casino.

August 8, 2016

Data Drought: The Struggle to Build Evidence in Vascular Medicine & Intervention

How VIVA Physicians is working to answer questions about treatment of vascular disease.

March 3, 2016

IN.PACT Admiral Drug-Coated Balloon Cost-Effectiveness Study and Global Study Results of In-Stent Restenosis Population Highlighted in Late Breaking Clinical Trials at VIVA 2015

Medtronic plc (NYSE: MDT) adds to the robust data for its IN.PACT® Admiral® drug-coated balloon (DCB) with the presentation of both its formal cost-effectiveness analysis from the U.S. cohort of the IN.PACT SFA Trial and clinical results from the in-stent restenosis cohort data from Medtronic's IN.PACT Global Study.

November 3, 2015

Medtronic Unveils New Aortic and Peripheral Data from Two Late-Breaking Clinical Trials at VIVA 2015

Medtronic plc (NYSE: MDT) today announced new clinical data in interventional treatments for aortic and peripheral vascular diseases in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2015.

November 3, 2015

Silk Road Medical announces 30 day results in the Roadster clinical trial for carotid artery revascularization

Sunnyvale, CA. -- Silk Road Medical, Inc. announced the 30 day outcomes from the ROADSTER IDE Study at the VIVA 2014 Vascular Interventional Advances Annual Conference in Las Vegas, Nevada. The trial studied the treatment of carotid artery stenosis with a new device and hybrid procedure combining the best elements of carotid endarterectomy (CEA) and carotid artery stenting (CAS).

November 10, 2014

Around the web

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."